Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: $3.64 to $3.98
• 50-Day Range: $3.37 to $4.66
• 52-Week Range: $0.52 to $5.92
• Volume: 1.19 million shs
• Average Volume: 1.21 million shs
• Market Capitalization: $256.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 40% of companies evaluated by MarketBeat, and ranked 713th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Neuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neuronetics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 8.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.12% of the outstanding shares of Neuronetics have been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Neuronetics has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.12% of the outstanding shares of Neuronetics have been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Neuronetics has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.18

News Sentiment

Neuronetics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Neuronetics this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.

MarketBeat Follows

2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.80% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STIM Stock Analysis - Frequently Asked Questions

How have STIM shares performed this year?

Neuronetics' stock was trading at $1.61 at the beginning of the year. Since then, STIM stock has increased by 142.2% and is now trading at $3.90.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) announced its earnings results on Tuesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business earned $38.11 million during the quarter, compared to the consensus estimate of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative trailing twelve-month return on equity of 156.36%.
Read the conference call transcript.

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Top institutional shareholders of Neuronetics include Geode Capital Management LLC (1.33%), AdvisorShares Investments LLC (0.20%), Bay Colony Advisory Group Inc d b a Bay Colony Advisors (0.13%) and JPMorgan Chase & Co. (0.10%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, William Andrew Macan, Robert Cascella, Stephen Furlong and Glenn P Muir.
View institutional ownership trends.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:STIM
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuronetics: $5.00
• High Price Target: $7.00
• Low Price Target: $3.00
• Potential Upside/Downside: +29.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.71 million
• Net Margins: -43.47%
• Pretax Margin: -43.70%
• Return on Equity: -156.36%
• Return on Assets: -35.69%

Debt

• Debt-to-Equity Ratio: 1.76
• Current Ratio: 2.02
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: $74.89 million
• Price / Sales: 3.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 8.04

Miscellaneous

• Outstanding Shares: 66,120,000
• Free Float: 59,645,000
• Market Cap: $255.22 million
• Optionable: Optionable
• Beta: 1.78